Christopher Guttman-McCabe - Aug 6, 2024 Form 4 Insider Report for Anterix Inc. (ATEX)

Role: Chief Reg & Comm Officer
Signature: s/ Gena L. Ashe, Attorney-in-Fact
Stock symbol: ATEX
Transactions as of: Aug 6, 2024
Transactions value $: $0
Form type: 4
Date filed: 8/8/2024, 05:01 PM
Previous filing: Jul 15, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ATEX	Stock Option (Right to Buy)	Award	$0	+85K		$0.00	85K	Aug 6, 2024	Common Stock	85K	$33.56	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On March 27, 2024, the Compensation Committee of the Board of Directors of the Issuer granted the Reporting Person the stock options, at a strike price of $33.56 per share based upon the closing price of the Issuer's common stock on the Nasdaq on such date. In accordance with Nasdaq Listing Rules, the granted stock options were subject to, and were not exercisable until, the Issuer's stockholders approved an authorization of minimum shares of common stock underlying such stock options to exercise the referenced award. On August 6, 2024, stockholders of the Issuer approved Amendment No. 1 to the Issuer's 2023 Stock Plan, which authorized an additional 1,100,000 shares under the Issuer's 2023 Stock Plan and satisfied the award conditions of the Reporting Person's stock option award.
F2	The option shares will vest and become exercisable by the Reporting Person, if he is employed by the Issuer, on March 27, 2027, unless exercisable sooner in accordance with the terms of the award agreement or any other applicable agreement, arrangement or policy of the Issuer.

Content

On March 27, 2024, the Compensation Committee of the Board of Directors of the Issuer granted the Reporting Person the stock options, at a strike price of $33.56 per share based upon the closing price of the Issuer's common stock on the Nasdaq on such date. In accordance with Nasdaq Listing Rules, the granted stock options were subject to, and were not exercisable until, the Issuer's stockholders approved an authorization of minimum shares of common stock underlying such stock options to exercise the referenced award. On August 6, 2024, stockholders of the Issuer approved Amendment No. 1 to the Issuer's 2023 Stock Plan, which authorized an additional 1,100,000 shares under the Issuer's 2023 Stock Plan and satisfied the award conditions of the Reporting Person's stock option award.

The option shares will vest and become exercisable by the Reporting Person, if he is employed by the Issuer, on March 27, 2027, unless exercisable sooner in accordance with the terms of the award agreement or any other applicable agreement, arrangement or policy of the Issuer.